Quelle: Michal Jarmoluk auf Pixabay
CMT2A Research Update: Understanding the SARM1 Approach
In this article, you will learn how the SARM1 approach works in CMT2A research and what role ASHA-624 plays.
Research into CMT2A is evolving. It is not a breakthrough, but it is a promising approach worth understanding.
The company Asha Therapeutics is working together with the CMT Research Foundation on a compound designed to block a key mechanism of nerve degeneration.
Here is a clear overview of what this means and why it matters.
What Current CMT2A Research Focuses On
CMT2A is caused by mutations in the MFN2 gene. This gene is important for mitochondrial function. When MFN2 is disrupted, long nerve fibers are placed under continuous stress.
One protein plays a central role in this process: SARM1.
When SARM1 is activated, it triggers a biochemical pathway that leads to the degeneration of nerve fibers. This process often begins at the end of the axon and gradually progresses backward.
Animal models have already shown that the disease can be almost completely prevented when SARM1 is genetically disabled.
This is the foundation of the current research approach.
What Asha Therapeutics Is Investigating
Asha Therapeutics is developing a compound called ASHA-624. It is a SARM1 inhibitor.
The goal is to block SARM1 in such a way that nerve degeneration does not start in the first place.
In the current research program, ASHA-624 is being studied in two main areas:
- in cells from people with CMT2A to observe how the compound affects mitochondrial dysfunction
- in animal models that replicate the progression of CMT2A
At this stage, all research is preclinical. There are currently no human trials and no reliable timeline for when that might change.
Why This Approach Matters
This approach is considered interesting because it targets a central mechanism of the disease.
- SARM1 appears to play a key role in axonal degeneration
- animal studies suggest that blocking it may improve function
- ASHA-624 has also been studied in the context of ALS, where similar mechanisms are involved
However, it is important to be realistic. This is an approach, not a finished treatment.
What This Means for People with CMT2A
In short: nothing concrete yet.
The research is still at an early stage. At the same time, it focuses on a mechanism that is well understood in CMT2A.
If laboratory results translate into clinical outcomes, this could eventually lead to human trials. For now, this remains a future possibility.
I will share updates here as new developments emerge.
If you are interested in daily life with CMT, you can read more here: Living with Charcot-Marie-Tooth